



VivoSight
Dx PRO

Transform your
patients'
skin health with
next-gen
OCT imaging

Optical Coherence Tomography, OCT
Cleared for clinical use

www.vivosight.com

VivoSight Dx Pro - Optical Coherence Tomography



Professor Christopher Zachary
University of California, Irvine
using VivoSight to scan a patient.



Subjective,
qualitative visual
examination
with invasive,
time-consuming
biopsy








THEN

Reimagine how
you examine skin

NOW

AI-informed,
rapid, repeatable,
non-invasive
imaging

Giving you the whole picture


-  Superior imaging for you, superior care for your patients
-  Unrivalled >1mm depth penetration, providing high-resolution, 3D skin imaging
-  Widest field-of-view 6mm x 6mm scan enables visualization of entire lesion
-  Real-time placement of VivoAID image-markers during scan acquisition
-  Full 3D scan acquired in just 15 seconds
-  Completely non-invasive. Better accepted by your patients
-  Real-time imaging enables diagnosis and treatment to be initiated within a single patient visit

Rapid scanning, simple interpretation

Live camera view to guide scan placement on lesion



Real time 3D render of OCT image including skin surface
AI-generated image markers



Enface top view of 6mm x 6mm scan area at any desired depth


Image markup tools for your reports

VivoAID places BCC image markers

Cross-sectional image of skin to >1mm depth

A Better solution for you and your patients

With substantial Level 1 clinical evidence, OCT skin imaging is now included in pan-European³ and national⁴ guidelines for the diagnosis and treatment of NMSC.




Building Diagnostic Confidence

The unrivalled 6mm x 6mm OCT field of view with VivoSight Dx Pro ensures that you can quickly and confidently view the entire lesion. Only VivoSight provides OCT skin imaging to a depth of >1mm, essential for BCC characterisation. Studies have shown that it can enable superior diagnosis of early-stage BCC compared with traditional clinical/dermatoscopic approaches.¹

Substantial Clinical Evidence

VivoSight has been found to be "non-inferior" to regular punch biopsy in the diagnosis and treatment of BCC.² As the leading dermatological OCT imaging system it has performed over 200,000 patient scans to-date, and has been used in over 500 peer-reviewed publications worldwide.

"In 66% of patients, a biopsy could be avoided, thus minimising treatment delay and avoiding an invasive procedure."²



Scar and Pain Free

VivoSight Dx Pro imaging is entirely non-invasive and has been shown to reduce the need for and number of punch biopsies.^{1,2} Your patients will value the reduction in invasive procedures and avoidance of scarring in cosmetic skin regions.

Harness the Power of AI

VivoSight Dx Pro makes OCT skin imaging accessible to every dermatologist. Easier to learn and faster to use, image-markers placed by VivoAID provide a powerful training tool.

"If I suspect a basal cell carcinoma, really all my patients get an OCT examination. The quality of the imaging is now so good that you are not fishing in the dark but can definitely say whether or not you have a BCC." Dr. Marco Fuchs, Kamp-Lintfort, Germany

Speeding and Simplifying the Patient Journey

Removing the need for biopsy in many NMSC patients enables diagnosis and treatment in a single patient visit. Better for you, better for your patients.

"The measurement times for optical coherence tomography are so short that diagnosis of multiple lesions is possible within a short time."⁵

"...a punch biopsy with 1 week waiting time for the results can be replaced by a one-stop-shop approach in around 2/3 of suspected basal cell carcinoma cases."²

"...strong correlation of tumour and skin layer thickness measurement of BCCs and AKs using OCT with histology."⁷

VivoSight contributes at every step in the patient journey

"Dermatoscopy, confocal laser microscopy and optical coherence tomography can be used to diagnose actinic keratosis and squamous cell carcinoma of the skin when findings are clinically unclear."⁵

"...good discrimination of superficial BCC from non-superficial BCC and non-BCC lesions..."⁶

"...clinical/dermoscopic examination + OCT resulted in a significant increase in sensitivity for diagnosing recurrent or residual BCC after topical treatment of sBCC without compromising specificity."⁸

OUTSTANDING SUPPORT MEETS GROUNDBREAKING TECHNOLOGY

When adopting VivoSight you can be confident of receiving comprehensive and timely support provided by Michelson Diagnostics' Product Experts and our trained and certified local partners. We will provide product installation,

full in-service training, and lifetime support for every system. Customer service is always our number one priority. A comprehensive range of Support Contracts is available.

VivoSight Dx Pro is a Class 1 Laser Product

References:

- 1 Markowitz, O. et al. J Clin Aesthet Dermatol. 2015, 8(10): 14-20.
- 2 Adan, F. et al. Lancet Oncology. 2022, 23(8) 1087-1096
- 3 Peris, K. et al. European J of cancer. 2019, 118:10-34
- 4 Lang, B. et al. Journal der Deutschen Dermatologischen Gesellschaft. 2019, 17:94-103

- 5 Leiter, U. et al. Eu J. C. Skin Cancer (2023) 1: 1-102
- 6 Adan, F. et al. Acta Dermatovenereologica. (2021), 30:101
- 7 Schuh, S., et al. JEADV, (2016), 30:1021
- 8 Wolswijk T., et al. JADV. (2023). 89:728

VivoSight Dx Pro is protected by granted and pending national and international patents



International

Michelson Diagnostics Ltd
Units 1&2 Maidstone Innovation Centre
Gidds Pond Way, Maidstone
Kent ME14 5FY
United Kingdom
T: +44 (0)20 8308 1695
info@vivosight.com

United States

Michelson Diagnostics Inc.
Atascadero,
CA 93422
T: (408) 504-7391
info.us@vivosight.com

www.vivosight.com